[ad_1]
The Swiss pharmaceutical group Roche Holdings is about to enter into an agreement to acquire the US biotechnology company Spark Therapeutics Inc., the Wall Street Journal reported on Saturday, citing people close to the case.
The deal for Spark could be announced Monday, if not earlier, at a price of nearly $ 5 billion, but could still fail, the Journal quoted unidentified sources as saying. Spark's market value was just under $ 2 billion at the close of trading on Friday.
The newspaper reported that there was at least one other unidentified bidder for Spark on Friday.
Roche and Spark officials said their companies did not comment on market rumors.
Spark is a gene therapy company with a portfolio of potential products for blindness, hemophilia and neurodegenerative diseases.
[ad_2]
Source link